Replies to post #47383 on Cytodyn Inc (CYDY)

[finesand]

T0m, it is show down ..

Remember when we talked about the THERF chart pre BLA and approval and saw the good dip right before?

Must have been years ago (o8>

Also CYDY's super dips never lasted long w/o bad news.

But we know the real decision is getting closer.
Could be a consolidation triangle from here into.

This was just a volatility breeze, MMs handing over shares.
IMHO

Licensing deal or not. That is the big question.

EDIT: I would go so far that CYDY's licensing deal is THERF's FDA approval,
as CYDY's Combo approval is very highly likely a sure thing (NP: Read the manual again lol).

OK, was last post - so good night.

2018-05-30 $10.85 TH Announces US$50 Million Bought Deal Offering
2018-05-30 $10.85 TH and EMD Serono Agree on Early and Final Payment

2018-05-16 $10.87
2018-05-11 $ 9.00 TH Announces that National Institute of Health will Support Study of EGRIFTA® in Non-HIV Patients with Non-Alcoholic Fatty Liver Disease

2018-05-07 $ 8.68
2018-05-01 $ 7.36 FDA RELEASES THERATECHNOLOGIES FROM POST-APPROVAL COMMITMENTS RELATED TO EGRIFTA® (TESAMORELIN FOR INJECTION)

2018-03-06 $ 7.12 Theratechnologies Announces FDA Approval of Trogarzo
2018-03-05 $ 5.47

2017-11-14 $ 5.17
2017-11-13 $ 5.78 Theratechnologies Announces Decision by the FDA to Extend the Ibalizumab Review Period to April 3, 2018
2017-11-10 $ 5.95

2017-10-11 $ 6.43
2017-09-29 $ 6.04
2017-09-18 $ 5.98 IBALIZUMAB Long-Term Safety and Efficacy Data to be Presented at IDWEEK 2017 in SAN DIEGO on 10/4 - 10/8

2017-06-30 $ 6.59 FDA Grants Priority Review to HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab

2017-05-03 $ 4.74 Theratechnologies Partner Submits Biologics License Application for HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab

2017-03-06 $ 3.68 Theratechnologies Acquires Commercial Rights to Ibalizumab in the European Union and Four Additional Territories

2017-02-15 $ 3.23
2017-02-14 $ 2.97 Theratechnologies Announces New Data from the Pivotal Phase III Trial of HIV Monoclonal Antibody and Long-Acting Investigational Antiretroviral Ibalizumab
2017-02-07 $ 2.54

2016-10-28 $ 2.52 Results of HIV Biologic and Long-Acting Investigational Antiretroviral Ibalizumab to be Presented in Late-Breaker Session at IDWeek 2016 on 2016-10-29
Initial results were announced on 2016-05-24
2016-09-19 $ 1.95

2016-08-18 $ 2.03 Ibalizumab Phase III Study Primary End-Point Results To Be Presented At IDWEEK 2016
Presentation on 2016-10-29

2016-06-01 $ 2.65
2016-05-24 $ 1.95 Initial results of HIV Biologic and Long-Acting Investigational Antiretroviral Ibalizumab,
2016-05-13 $ 1.56

2016-04-28 $ 1.71 Theratechnologies Announces Completion of Enrollment for Phase III Ibalizumab Trial

2016-03-31 $ 1.57
2016-03-18 $ 1.09 Theratechnologies and TaiMed Biologics sign exclusive Marketing and Distribution Agreement for Ibalizumab
2016-03-17 $ 0.99

[chumppunk]

d0lphint0m- you say "I still stick with Misiu's assessment" … I do as well without question. The problem lies within the OTC, financing and everything is based on it being on the OTC. Can't change lender requirements. We'll have to deal with it till they reach a point to get off and present a lender with a better scenario. Hopefully around the corner.
Chump